Vogenx, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VOGX | VTVT | PHAT | VOR | NBP | RGNX | |
|---|---|---|---|---|---|---|
| Market cap | 293.09M | 95.01M | 461.74M | 1.24B | 117.16M | 508.96M |
| P/E (TTM) | — | — | — | 0.1 | — | — |
| Forward P/E | — | -5.5 | 5.9 | -5.7 | -0.8 | -2.6 |
| Price/book | -58.4 | 3.8 | -1.3 | -9.0 | 0.6 | 5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +57.92% | −2.85% | −56.78% | −5.02% | −76.29% | −34.28% |
| Today | −3.90% | +2.04% | −1.05% | +1.31% | 0.00% | +1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VOGX news ›Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Alcoa Corporation Reports Third Quarter 2026 Results EMERGE will test two mizagliflozin doses against placebo, with combined Level 2 and Level 3 hypoglycemic events as its primary endpoint. Vogenx (VOGX) has initiated EMERGE, a Phase 2b…
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial readiness as the Company advan
Vogenx grants Kenneth John Toombs 50,000 options
Annual vesting runs from October 2, 2027 through October 2, 2029, subject to continued service. Director Kenneth John Toombs received the grant. Vogenx grants Kenneth John Toombs 50,000 options Each option installment depends on Kenneth…
Vogenx awards director Pieraccini 50,000 options
The options vest in three annual installments from October 2, 2027, through October 2, 2029, subject to continued service, and expire October 2, 2036. Vogenx awards director Pieraccini 50,000 options The award vests in annual installments…
Raleigh-based Vogenx launches IPO, raises $81.3M for metabolic disease drug development
A Raleigh-based biopharmaceutical company is starting its next chapter as a public company after raising $81.3 million in an initial public offering. Vogenx Inc. celebrated its Nasdaq debut with an Opening Bell ceremony in August after…
Vogenx Director Peter Pieraccini Granted 50,000 Stock Options at $18.23 Exercise Price
Can Fiber Help Verizon (NYSE:VZ) Firm Up Its Cash Flow? Can Pfizer (NYSE:PFE) Revive Its Outlook After Muted Guidance? Is Citigroup's (NYSE:C) Turnaround Ready for Its Quarterly Checkpoint? On October 6, 2026, Vogenx, Inc. Director Peter…
Vogenx grants CEO James Green 155,000 stock options
The options carry a $20.053 exercise price per share and expire October 2, 2031. James Green received the award on October 2, 2026, according to Form 4. Vogenx grants CEO James Green 155,000 stock options James Green is also identified as…
Vogenx grants CFO Steven R. Delmar 155,000 stock options
Options priced at $18.23 go to Vogenx (VOGX) CFO Steven R. Delmar in a 155,000-option grant. Stock Titan Vogenx grants CFO Steven R. Delmar 155,000 stock options The chief financial officer's option award vests in annual installments…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net7
- kalkinemedia.com2
- digitaljournal.com1
- ncbiotech.org1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.